Showing 841-850 of 1576 results for "".
- Eric D. Donnenfeld, MD, of OCLI Vision Named America’s Best Eye Doctor by Newsweekhttps://modernod.com/news/eric-d-donnenfeld-md-of-ocli-vision-named-americas-best-eye-doctor-by-newsweek/2479447/Eric D. Donnenfeld, MD has been named “America’s Best Eye Doctor 2021” by Newsweek. Dr. Donnenfeld ranks first out of 150 ophthalmologists with a near perfect score for quality of care, continuity of care, and the quality of the technology used in his practice. Dr. Donnenfeld
- TFOS DEWS III Report Published with Updated Guidelines for Diagnosis and Management of DEDhttps://modernod.com/news/tfos-dews-iii-report-published-for-updated-guidelines-for-diagnosis-and-management-of-ded/2482849/The Tear Film and Ocular Surface Society (TFOS) has released the TFOS DEWS III report, its third set of reports exploring the diagnosis and management of dry eye disease. The findings of the TFOS DEWS III report were published in the
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Tarsus Partners With John Cena on Demodex Blepharitis Awareness Campaignhttps://modernod.com/news/tarsus-partners-with-john-cena-on-demodex-blepharitis-awareness-campaign/2487094/Tarsus Pharmaceuticals is partnering with celebrity John Cena on a campaign to raise awareness of Demodex blepharitis. As part of this campaign, Cena will detail his own experience with Demodex blepharitis and lotilaner ophthalmic solution 0.25% (Xdemvy) the first FDA-approved t
- ViaLase and the John A. Moran Eye Center Partner to Accelerate Glaucoma Research and Innovationhttps://modernod.com/news/vialase-and-the-john-a-moran-eye-center-announce-research-partnership-to-accelerate-glaucoma-research-and-innovation/2482573/ViaLase announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will explore aqueous outflow dynamics of ViaLase’s ViaLase laser procedure, utilizing Moran’s iPerf
- AcuFocus Appoints Industry Leader John Garland as Global Vice President of Saleshttps://modernod.com/news/acufocus-appoints-industry-leader-john-garland-as-global-vice-president-of-sales/2479257/AcuFocus announced that it has appointed John Garland as its Global Vice President of Sales. In his new role, he will be responsible for global sales strategy and will focus initially on building the US sales field team. Mr. Garland brings more than 30 years of experience to the position w
- John Weiss Launches the Merilas 810 Shortpulse Laser in the UKhttps://modernod.com/news/john-weiss-launches-the-merilas-810-shortpulse-laser-in-the-uk/2478380/John Weiss & Son has announced the launch of the Merilas 810 shortpulse laser in the UK. The Merilas 810 shortpulse laser provides glaucoma and retina treatments and offers new laser therapy for advanced and end-stage glaucoma. The system offers Transscleral Cyclophotocoagulation (TSCP
- Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Reporthttps://modernod.com/news/nordic-pharmas-lacrifill-canalicular-gel-highlighted-in-landmark-dews-iii-report/2482927/Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and O
- AMA Issues CPT Category III Codes for Artificial Iris Implantationhttps://modernod.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/VEO Ophthalmics announced that the American Medical Association (AMA) has issued three CPT codes for the “Insertion of Iris Prosthesis.” The CPT Category III codes are: 0616T, 0617T, and 0618T and are effective July 1, 2020. Earlier this year, the
- LumiThera Announces Sustained Vision Improvement for 24 Months in Dry AMD Subjects from US LIGHTSITE III Trialhttps://modernod.com/news/lumithera-announces-sustained-vision-improvement-for-24-months-in-dry-amd-subjects-from-us-lightsite-iii-clinical-trial-data/2481469/LumiThera announced 24-month data from its LIGHTSITE III multicenter clinical trial which demonstrated sustained vision improvement in dry age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked